{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:24:24Z","timestamp":1791905064250,"version":"4.3.4"},"reference-count":186,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Cancer encompasses various elements occurring at the cellular and genetic levels, necessitating an immunotherapy capable of efficiently addressing both aspects. T cells can combat cancer cells by specifically recognizing antigens on them. This innate capability of T cells has been used to develop cellular immunotherapies, but most of them can only target antigens through major histocompatibility complexes (MHCs). New gene-editing techniques such as clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein 9 (CRISPR-cas9) can precisely edit the DNA sequences. CRISPR-cas9 has made it possible to generate genetically engineered chimeric antigen receptors (CARs) that can overcome the problems associated with old immunotherapies. In chimeric antigen receptor T (CAR-T) cell therapy, the patient\u2019s T cells are isolated and genetically modified to exhibit synthetic CAR(s). CAR-T cell treatment has shown remarkably positive clinical outcomes in cancers of various types. Nevertheless, there are various challenges that reduce CAR-T effectiveness in solid tumors. It is required to address these challenges in order to make CAR-T cell therapy a better and safer option. Combining CAR-T treatment with other immunotherapies that target multiple antigens has shown positive outcomes. Moreover, recently generated Boolean logic-gated advanced CARs along with artificial intelligence has expanded its potential to treat solid tumors in addition to blood cancers. This review aims to describe the structure, types, and various methods used to develop CAR-T cells. The clinical applications of CAR-T cells in hematological malignancies and solid tumours have been described in detail. In addition, this discussion has addressed the limitations associated with CAR-T cells, explored potential strategies to mitigate CAR-T-related toxicities, and delved into future perspectives.<\/jats:p>","DOI":"10.3390\/jcm13113202","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T06:08:14Z","timestamp":1717049294000},"page":"3202","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["CAR-T-Cell-Based Cancer Immunotherapies: Potentials, Limitations, and Future Prospects"],"prefix":"10.3390","volume":"13","author":[{"given":"Mahmood S.","family":"Choudhery","sequence":"first","affiliation":[{"name":"Department of Human Genetics & Molecular Biology, University of Health Sciences, Lahore 54600, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taqdees","family":"Arif","sequence":"additional","affiliation":[{"name":"Department of Human Genetics & Molecular Biology, University of Health Sciences, Lahore 54600, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruhma","family":"Mahmood","sequence":"additional","affiliation":[{"name":"Jinnah Hospital, Allama Iqbal Medical College, Lahore 54700, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9850-6234","authenticated-orcid":false,"given":"David T.","family":"Harris","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, College of Medicine, University of Arizona Health Sciences Biorepository, The University of Arizona, Tucson, AZ 85724-5221, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"ref_1","first-page":"719","article-title":"The development and causes of cancer","volume":"2","author":"Cooper","year":"2000","journal-title":"Cell A Mol. Approach"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e27456","DOI":"10.4161\/onci.27456","article-title":"The immune landscape of human tumors: Implications for cancer immunotherapy","volume":"3","author":"Bindea","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Fridman, W.H., Galon, J., Dieu-Nosjean, M.-C., Cremer, I., Fisson, S., Damotte, D., Pag\u00e8s, F., Tartour, E., and Saut\u00e8s-Fridman, C. (2011). Immune infiltration in human cancer: Prognostic significance and disease control. Current Topics in Microbiology and Immunology, Springer.","DOI":"10.1007\/82_2010_46"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41423-020-00530-6","article-title":"Human immunology and immunotherapy: Main achievements and challenges","volume":"18","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"9903","DOI":"10.1007\/s11033-022-07525-8","article-title":"Immunotherapy: An alternative promising therapeutic approach against cancers","volume":"49","author":"Gupta","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e96976","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ajh.26301","article-title":"Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials","volume":"96","author":"Westin","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_8","unstructured":"ImmPACT Bio (2023, September 02). ImmPACT Bio Announces FDA Clearance of IND for Novel Bispecific CAR to Treat Aggressive B-Cell Lymphoma. Available online: https:\/\/tdg.ucla.edu\/immpact-bio-announces-fda-clearance-ind-novel-bispecific-car-treat-aggressive-b-cell-lymphoma#:~:text=(%E2%80%9CImmPACT%20Bio%E2%80%9D)%2C,a%20bispecific%20%E2%80%9COR%2DGate%E2%80%9D."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1250508","DOI":"10.3389\/fmmed.2023.1250508","article-title":"Elaborating the potential of Artificial Intelligence in automated CAR-T cell manufacturing","volume":"3","author":"Hort","year":"2023","journal-title":"Front. Mol. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Carbone, A. (2020). Cancer classification at the crossroads. Cancers, 12.","DOI":"10.3390\/cancers12040980"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","article-title":"Cancer treatment therapies: Traditional to modern approaches to combat cancers","volume":"50","author":"Kaur","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Tan, S., Li, D., and Zhu, X. (2020). Cancer immunotherapy: Pros, cons and beyond. Biomed. Pharmacother., 124.","DOI":"10.1016\/j.biopha.2020.109821"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2174\/1389201016666150619114554","article-title":"Immunotherapy approaches in cancer treatment","volume":"16","author":"Klener","year":"2015","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.5732\/cjc.014.10123","article-title":"Cancer immunotherapy in clinical practice\u2014The past, present, and future","volume":"33","author":"Goel","year":"2014","journal-title":"Chin. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e000482","DOI":"10.1136\/esmoopen-2018-000482","article-title":"New emerging targets in cancer immunotherapy: The role of LAG3","volume":"4","author":"Puhr","year":"2019","journal-title":"ESMO Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: Moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.3390\/cancers3043856","article-title":"Cytokines in cancer immunotherapy","volume":"3","author":"Lee","year":"2011","journal-title":"Cancers"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/1097-0142(196611)19:11<1743::AID-CNCR2820191143>3.0.CO;2-U","article-title":"Effect of leukocytes on transplantability of human cancer","volume":"19","author":"Southam","year":"1966","journal-title":"Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1056\/NEJM197905103001902","article-title":"Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts","volume":"300","author":"Weiden","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2","volume":"86","author":"Rosenberg","year":"1994","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e0004","DOI":"10.5041\/RMMJ.10179","article-title":"Adoptive T cell immunotherapy for cancer","volume":"6","author":"Perica","year":"2015","journal-title":"Rambam Maimonides Med. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","article-title":"The urgent need to recover MHC class I in cancers for effective immunotherapy","volume":"39","author":"Garrido","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1038\/s41467-019-13368-y","article-title":"Engineering dendritic cell vaccines to improve cancer immunotherapy","volume":"10","author":"Perez","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI123955","article-title":"Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells","volume":"129","author":"Kamiya","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/icb.2017.6","article-title":"Antibody-dependent cell cytotoxicity: Immunotherapy strategies enhancing effector NK cells","volume":"95","author":"Ochoa","year":"2017","journal-title":"Immunol. Cell Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.4110\/in.2022.22.e4","article-title":"Development of bispecific antibody for cancer immunotherapy: Focus on T cell engaging antibody","volume":"22","author":"Moon","year":"2022","journal-title":"Immune Netw."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: The promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Zmievskaya, E., Valiullina, A., Ganeeva, I., Petukhov, A., Rizvanov, A., and Bulatov, E. (2021). Application of CAR-T cell therapy beyond oncology: Autoimmune diseases and viral infections. Biomedicines, 9.","DOI":"10.3390\/biomedicines9010059"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1038\/srep03571","article-title":"Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor","volume":"4","author":"Zhang","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1111\/j.1742-4658.2011.08207.x","article-title":"The association of heavy and light chain variable domains in antibodies: Implications for antigen specificity","volume":"278","author":"Chailyan","year":"2011","journal-title":"FEBS J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","article-title":"Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-15-0139","article-title":"Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity","volume":"75","author":"Caruso","year":"2015","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coi.2015.01.002","article-title":"Designing chimeric antigen receptors to effectively and safely target tumors","volume":"33","author":"Jensen","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: Design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/01.cji.0000161397.96582.59","article-title":"The role of extracellular spacer regions in the optimal design of chimeric immune receptors: Evaluation of four different scFvs and antigens","volume":"28","author":"Guest","year":"2005","journal-title":"J. Immunother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/gt.2015.4","article-title":"Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model","volume":"22","author":"Walseng","year":"2015","journal-title":"Gene Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.4049\/jimmunol.1103495","article-title":"An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo","volume":"189","author":"Zhang","year":"2012","journal-title":"J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/imr.12131","article-title":"Design and development of therapies using chimeric antigen receptor-expressing T cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/sj.gt.3302023","article-title":"T-cell activation by recombinant immunoreceptors: Impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells","volume":"10","author":"Heuser","year":"2003","journal-title":"Gene Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.4049\/jimmunol.0900447","article-title":"A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity","volume":"183","author":"Zhao","year":"2009","journal-title":"J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.4049\/jimmunol.0901766","article-title":"The optimal antigen response of chimeric antigen receptors harboring the CD3\u03b6 transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR\/CD3 complex","volume":"184","author":"Bridgeman","year":"2010","journal-title":"J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nri1248","article-title":"CD28-mediated co-stimulation: A quantitative support for TCR signalling","volume":"3","author":"Acuto","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-016-0357-z","article-title":"Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia","volume":"9","author":"Cai","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-016-0299-5","article-title":"Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy","volume":"9","author":"Hu","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.3324\/haematol.2010.026310","article-title":"Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: Improvement of their immune activity by expression of CD33-specific chimeric receptors","volume":"95","author":"Marin","year":"2010","journal-title":"Haematologica"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In vivo fate and activity of second-versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin\u2019s lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: The fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1021\/sb3001112","article-title":"Synthesizing biomolecule-based Boolean logic gates","volume":"2","author":"Miyamoto","year":"2013","journal-title":"ACS Synth. Biol."},{"key":"ref_57","first-page":"507","article-title":"Coopting T cell proximal signaling molecules enables Boolean logic-gated CAR T cell control","volume":"615","author":"Tousley","year":"2022","journal-title":"bioRxiv"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"780399","DOI":"10.3389\/fimmu.2021.780399","article-title":"Implementing logic gates for safer immunotherapy of cancer","volume":"12","author":"Savanur","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2114254","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Dejenie","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1\u2013and CTLA-4\u2013based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable manufacturing of CAR T cells for cancer immunotherapy","volume":"2","author":"Elsallab","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: Foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol. Ther.-Oncolyt."},{"key":"ref_63","unstructured":"Wang, X., Stefanski, J., Borquez-Ojeda, O., Qu, J., Hack, A., and He, Q. (2015). Comparison of CTS Dynabeadsc CD3\/CD28, Miltenyi TransAct CD3\/28 and ExpAct Beads for Large-Scale CAR T Cell Manufacturing, European Society of Gene and Cell Therapy Collaborative Congress."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"17832","DOI":"10.1038\/s41598-020-74595-8","article-title":"Expamers: A new technology to control T cell activation","volume":"10","author":"Poltorak","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1073\/pnas.86.16.6077","article-title":"Cationic liposome-mediated RNA transfection","volume":"86","author":"Malone","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ymthe.2005.07.688","article-title":"High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation","volume":"13","author":"Zhao","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-017-0444-9","article-title":"Chimeric antigen receptor T cells: A novel therapy for solid tumors","volume":"10","author":"Yu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/mt.2015.4","article-title":"Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression","volume":"23","author":"Curran","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41467-017-00505-8","article-title":"Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers","volume":"8","author":"Moffett","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Piscopo, N.J., Mueller, K.P., Das, A., Hematti, P., Murphy, W.L., Palecek, S.P., Capitini, C.M., and Saha, K. (2018). Bioengineering solutions for manufacturing challenges in CAR T cells. Biotechnol. J., 13.","DOI":"10.1002\/biot.201700095"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jcyt.2013.06.003","article-title":"Simplified process for the production of anti\u2013CD19-CAR\u2013engineered T cells","volume":"15","author":"Tumaini","year":"2013","journal-title":"Cytotherapy"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/307241a0","article-title":"Transcriptional interference in avian retroviruses\u2014Implications for the promoter insertion model of leukaemogenesis","volume":"307","author":"Cullen","year":"1984","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/gt.2011.40","article-title":"The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor","volume":"18","author":"Jin","year":"2011","journal-title":"Gene Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/leu.2016.180","article-title":"Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors","volume":"31","author":"Monjezi","year":"2017","journal-title":"Leukemia"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/cbin.11972","article-title":"Prime editing: A potential treatment option for \u03b2-thalassemia","volume":"47","author":"Arif","year":"2023","journal-title":"Cell Biol. Int."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ymeth.2017.04.003","article-title":"Genome editing via delivery of Cas9 ribonucleoprotein","volume":"121","author":"DeWitt","year":"2017","journal-title":"Methods"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jbiotec.2015.04.024","article-title":"Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection","volume":"208","author":"Liang","year":"2015","journal-title":"J. Biotechnol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s13238-017-0410-x","article-title":"Advancing chimeric antigen receptor T cell therapy with CRISPR\/Cas9","volume":"8","author":"Ren","year":"2017","journal-title":"Protein Cell"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Zhang, C., Liu, J., Zhong, J., and Zhang, X. (2017). Engineering CAR-T cells. Biomark. Res., 5.","DOI":"10.1186\/s40364-017-0102-y"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Ganeeva, I., Zmievskaya, E., Valiullina, A., Kudriaeva, A., Miftakhova, R., Rybalov, A., and Bulatov, E. (2022). Recent Advances in the Development of Bioreactors for Manufacturing of Adoptive Cell Immunotherapies. Bioengineering, 9.","DOI":"10.3390\/bioengineering9120808"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.5966\/sctm.2014-0294","article-title":"Concise review: Process development considerations for cell therapy","volume":"4","author":"Campbell","year":"2015","journal-title":"Stem Cells Transl. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jss.2013.09.027","article-title":"Cryopreservation of whole adipose tissue for future use in regenerative medicine","volume":"187","author":"Choudhery","year":"2014","journal-title":"J. Surg. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1007042","DOI":"10.3389\/fimmu.2022.1007042","article-title":"CAR-T manufactured from frozen PBMC yield efficient function with prolonged in vitro production","volume":"13","author":"Menges","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"123","DOI":"10.54680\/fr23310110112","article-title":"Perspective: The Role of Cryopreservation Techniques in Manufacturing, Transport, and Storage of Car-T Therapy Products","volume":"44","author":"Stacey","year":"2023","journal-title":"Cryoletters"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2174\/1574888X11308050004","article-title":"Utility of cryopreserved umbilical cord tissue for regenerative medicine","volume":"8","author":"Choudhery","year":"2013","journal-title":"Curr. Stem Cell Res. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.jcyt.2014.08.012","article-title":"Cryopreservation can be used as an anti-aging strategy","volume":"16","author":"Choudhery","year":"2014","journal-title":"Cytotherapy"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Bojic, S., Murray, A., Bentley, B.L., Spindler, R., Pawlik, P., Cordeiro, J.L., Bauer, R., and de Magalh\u00e3es, J.P. (2021). Winter is coming: The future of cryopreservation. BMC Biol., 19.","DOI":"10.1186\/s12915-021-00976-8"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: Patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00262-022-03287-1","article-title":"Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: A systematic review and meta-analysis","volume":"72","author":"Owen","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1078-0432.CCR-20-1271","article-title":"Eradication of T-ALL cells by CD7-targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management","volume":"27","author":"Li","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12015-020-10092-9","article-title":"Treatment of aggressive T cell lymphoblastic lymphoma\/leukemia using anti-CD5 CAR T cells","volume":"17","author":"Feng","year":"2021","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells","volume":"30","author":"Pinz","year":"2016","journal-title":"Leukemia"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.7150\/jca.28952","article-title":"Preclinical targeting of human acute myeloid leukemia using CD4-specific chimeric antigen receptor (CAR) T cells and NK cells","volume":"10","author":"Salman","year":"2019","journal-title":"J. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"107731","DOI":"10.1016\/j.intimp.2021.107731","article-title":"Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia","volume":"96","author":"Xie","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/s41375-018-0285-8","article-title":"CAR T-cells for T-cell malignancies: Challenges in distinguishing between therapeutic, normal, and neoplastic T-cells","volume":"32","author":"Alcantara","year":"2018","journal-title":"Leukemia"},{"key":"ref_98","first-page":"25","article-title":"Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia","volume":"140","author":"Maciocia","year":"2022","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_99","first-page":"2120","article-title":"Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas","volume":"131","author":"Fanale","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.exphem.2006.03.003","article-title":"Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs","volume":"34","author":"Nguyen","year":"2006","journal-title":"Exp. Hematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1945804","DOI":"10.1080\/2162402X.2021.1945804","article-title":"Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML","volume":"10","author":"Meyer","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","article-title":"CAR T-cells targeting FLT3 have potent activity against FLT3\u2212 ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib","volume":"32","author":"Jetani","year":"2018","journal-title":"Leukemia"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","article-title":"CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T cell therapy in hematological malignancies: Current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_107","first-page":"1830","article-title":"Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia","volume":"138","author":"Jetani","year":"2021","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1002\/ctm2.346","article-title":"A phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia","volume":"11","author":"Li","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1158\/1078-0432.CCR-21-3803","article-title":"FDA approval summary: Idecabtagene vicleucel for relapsed or refractory multiple myeloma","volume":"28","author":"Sharma","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.18632\/oncotarget.26792","article-title":"Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma","volume":"10","author":"Sun","year":"2019","journal-title":"Oncotarget"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond","volume":"270","author":"Janmaat","year":"2016","journal-title":"Immunol. Rev."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41467-020-14619-z","article-title":"CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide","volume":"11","author":"Radhakrishnan","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41416-018-0346-9","article-title":"Cell-based immunotherapy approaches for multiple myeloma","volume":"120","author":"Kriegsmann","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_114","first-page":"2838","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: An open-label phase I trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/bloodadvances.2021005385","article-title":"Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma","volume":"6","author":"Voorhees","year":"2022","journal-title":"Blood Adv."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"984864","DOI":"10.3389\/fimmu.2022.984864","article-title":"Chimeric antigen receptor T cells applied to solid tumors","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40259-015-0122-9","article-title":"Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer","volume":"29","author":"Hillerdal","year":"2015","journal-title":"BioDrugs"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/jco.2013.31.6_suppl.72","article-title":"Chimeric antigen receptor (CAR+) modified T cells targeting prostate specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)","volume":"31","author":"Slovin","year":"2013","journal-title":"Am. Soc. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/15384047.2020.1739952","article-title":"Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression","volume":"21","author":"Weimin","year":"2020","journal-title":"Cancer Biol. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/pros.23214","article-title":"Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: Possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response","volume":"76","author":"Junghans","year":"2016","journal-title":"Prostate"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41585-021-00488-8","article-title":"The potential of CAR T cell therapy for prostate cancer","volume":"18","author":"Wolf","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"ref_124","first-page":"1513","article-title":"Expression of c-met is a strong independent prognostic factor in breast carcinoma","volume":"82","author":"Ghoussoub","year":"1998","journal-title":"Cancer Interdiscip. Int. J. Am. Cancer Soc."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Yang, Y.-H., Liu, J.-W., Lu, C., and Wei, J.-F. (2022). CAR-T cell therapy for breast cancer: From basic research to clinical application. Int. J. Biol. Sci., 18.","DOI":"10.7150\/ijbs.70120"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: Results of phase I trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e1440169","DOI":"10.1080\/2162402X.2018.1440169","article-title":"CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41417-020-00259-4","article-title":"Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma","volume":"28","author":"Guo","year":"2021","journal-title":"Cancer Gene Therapy"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/14728222.2018.1498845","article-title":"MUC16 as a novel target for cancer therapy","volume":"22","author":"Aithal","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor\u2013modified T-cell therapy for CEA+ liver metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e001097","DOI":"10.1136\/jitc-2020-001097","article-title":"HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery","volume":"8","author":"Katz","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2021.39.3_suppl.74","article-title":"Updated data from the alloSHRINK phase 1 first-in-Human study evaluating CYAD-101, an innovative non-Gene-Edited allogeneic CAR-T, in metastatic colorectal cancer","volume":"39","author":"Prenen","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_136","first-page":"3862","article-title":"Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)","volume":"7","author":"Argani","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","article-title":"Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma","volume":"44","author":"Posey","year":"2016","journal-title":"Immunity"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1158\/1078-0432.CCR-19-2163","article-title":"CEACAM7 is an effective target for CAR T-cell therapy of pancreatic ductal adenocarcinoma","volume":"27","author":"Raj","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/jha2.356","article-title":"CAR T cell therapy in solid tumors: A review of current clinical trials","volume":"3","author":"Patel","year":"2022","journal-title":"EJHaem"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"CT036","DOI":"10.1158\/1538-7445.AM2019-CT036","article-title":"Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy","volume":"79","author":"Adusumilli","year":"2019","journal-title":"Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"815726","DOI":"10.3389\/fonc.2022.815726","article-title":"The Road to CAR T-Cell Therapies for Pediatric CNS Tumors: Obstacles and New Avenues","volume":"12","author":"Burns","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti\u2013PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: A phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: More room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1111\/bjh.17197","article-title":"Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy","volume":"192","author":"Jain","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: First-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e002723","DOI":"10.1136\/jitc-2021-002723","article-title":"Adoptive cellular therapy in solid tumor malignancies: Review of the literature and challenges ahead","volume":"9","author":"Kirtane","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","article-title":"Fully human Bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma","volume":"132","author":"Green","year":"2018","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.3389\/fimmu.2018.02268","article-title":"Effective targeting of TAG72+ peritoneal ovarian tumors via regional delivery of CAR-engineered T cells","volume":"9","author":"Murad","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"7168","DOI":"10.1158\/0008-5472.CAN-14-2458","article-title":"Trafficking of T cells into tumors","volume":"74","author":"Slaney","year":"2014","journal-title":"Cancer Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","article-title":"Regional delivery of chimeric antigen receptor\u2013engineered T cells effectively targets HER2+ breast cancer metastasis to the brain","volume":"24","author":"Priceman","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","article-title":"Optimization of IL13R\u03b12-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma","volume":"26","author":"Brown","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"ref_164","first-page":"1039","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)\u2013modified T cells: Refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","article-title":"Transgenic expression of IL15 improves antiglioma activity of IL13R\u03b12-CAR T cells but results in antigen loss variants","volume":"5","author":"Krenciute","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/asheducation-2016.1.567","article-title":"Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia","volume":"2016","author":"Frey","year":"2016","journal-title":"Hematology"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014Assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T cell toxicity: Current management and future directions","volume":"3","author":"Perales","year":"2019","journal-title":"Hemasphere"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/jamainternmed.2018.3931","article-title":"Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015\u20132016","volume":"178","author":"Moore","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e397912","DOI":"10.1200\/EDBK_397912","article-title":"high cost of chimeric antigen receptor T-cells: Challenges and solutions","volume":"43","author":"Cliff","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.omtm.2018.01.010","article-title":"The pharmacology of T cell therapies","volume":"8","author":"Milone","year":"2018","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"Hamieh","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"eaat6753","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci. Signal."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/leu.2017.57","article-title":"Fully human CD19-specific chimeric antigen receptors for T-cell therapy","volume":"31","author":"Sommermeyer","year":"2017","journal-title":"Leukemia"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","article-title":"Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL)","volume":"130","author":"Locke","year":"2017","journal-title":"Blood"},{"key":"ref_180","first-page":"697","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fphar.2014.00254","article-title":"Improving the safety of cell therapy products by suicide gene transfer","volume":"5","author":"Jones","year":"2014","journal-title":"Front. Pharmacol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_183","first-page":"64","article-title":"Artificial intelligence-developments in medicine in the last two years","volume":"5","author":"Galimova","year":"2019","journal-title":"Chronic Dis. Transl. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41587-023-01684-0","article-title":"Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia","volume":"41","author":"Gottschlich","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jamiaopen\/ooaa006","article-title":"Machine learning for early detection of sepsis: An internal and temporal validation study","volume":"3","author":"Bedoya","year":"2020","journal-title":"JAMIA Open"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s13287-021-02510-7","article-title":"A deep insight into CRISPR\/Cas9 application in CAR-T cell-based tumor immunotherapies","volume":"12","author":"Razeghian","year":"2021","journal-title":"Stem Cell Res. Ther."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/11\/3202\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:50:23Z","timestamp":1760107823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/11\/3202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":186,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["jcm13113202"],"URL":"https:\/\/doi.org\/10.3390\/jcm13113202","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]}}}